Ovid Therapeutics Inc. (OVID)
| Market Cap | 483.64M +1,858.1% |
| Revenue (ttm) | 7.25M +1,181.3% |
| Net Income | -17.14M |
| EPS | -0.23 |
| Shares Out | 173.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 577,591 |
| Open | 2.780 |
| Previous Close | 2.790 |
| Day's Range | 2.700 - 2.840 |
| 52-Week Range | 0.270 - 3.105 |
| Beta | 0.19 |
| Analysts | Strong Buy |
| Price Target | 4.60 (+64.58%) |
| Earnings Date | May 12, 2026 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's d... [Read more]
Financial Performance
In 2025, Ovid Therapeutics's revenue was $7.25 million, an increase of 1181.27% compared to the previous year's $566,000. Losses were -$17.14 million, -34.01% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price target is $4.6, which is an increase of 64.58% from the latest price.
News
Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)
“Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions,” stated Meg Alexander...
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safet...
Ovid Therapeutics files to sell 29.86M shares of common stock for holders
16:33 EDT Ovid Therapeutics (OVID) files to sell 29.86M shares of common stock for holders
Ovid Therapeutics Transcript: Status update
KCC2 direct activation is a transformative approach for psychotic disorders, with OV4071 showing strong preclinical efficacy and safety. The clinical strategy uses translational biomarkers for rapid proof-of-concept in schizophrenia, Parkinson’s disease psychosis, and Lewy body dementia, backed by broad IP and significant commercial potential.
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $4 from $2 and keeps a Buy rating on the shares. The company’s OV4071 oral KCC2 candidate is…
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Ovid Therapeutics (OVID) to $7 from $5 and keeps an Outperform rating on the shares. The firm highlights multiple updates…
Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
Roth Capital raised the firm’s price target on Ovid Therapeutics (OVID) to $5 from $3 and keeps a Buy rating on the shares. Phase 1 safety and tolerability results of…
Ovid Therapeutics Earnings Call Transcript: Q4 2025
Regulatory clearance for OV4071 and strong safety data for OV329 drive pipeline expansion, supported by $60M PIPE financing and potential $53M from warrant exercises, extending cash runway into 2029. New clinical programs target significant unmet needs in epilepsy and psychosis.
Ovid Therapeutics announces Phase 1 clearance for OV4071
The Company will initiate a Phase 1 trial for OV4071, a potential first-in-class, oral, direct activator of potassium-chloride cotransporter 2 following Human Research Ethics Committee approval of the...
Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)
Reports Q4 revenue $718,000, consensus $62,600. “We are achieving important steps forward in our mission to pioneer better, gentler medicines for disorders of the brain. We believe today’s data contin...
Ovid Therapeutics sees cash runway into late 2028
Cash, cash equivalents and marketable securities as of December 31, 2025 totaled $90.4 million.
Ovid Therapeutics announces OV239 data, indication expansion
Ovid announced new results from a 7 mg dose cohort evaluating the safety and tolerability of OV329, a next-generation GABA-AT inhibitor being developed for drug-resistant epilepsies. Following the cor...
Ovid Therapeutics prices 19.15M shares at $2.01 in private placement
Ovid Therapeutics (OVID) entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of $60M to the Company,…
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod...
Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing OV329, a novel GABA-AT inhibitor, into Phase II for epilepsy with promising safety and efficacy data, while also progressing OV4071, a KCC2 activator, into Phase I for CNS disorders including psychosis. Interim and pivotal data readouts are expected over the next year.
Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a CNS-focused pipeline with differentiated mechanisms, highlighted by OV329 for epilepsy, which shows strong efficacy and tolerability, and OV4071, a KCC2 activator targeting psychosis. Key clinical milestones are expected over the next 6–18 months.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by exces...
Ovid Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $4 price target
Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV
Ovid Therapeutics (OVID) announced results from its Phase 1 study of OV350, the first-ever Potassium-Chloride Cotransporter 2, KCC2, direct activator known to be dosed in humans. The study met its…
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings, n...
Ovid Therapeutics files to sell 125.06M shares of common stock for holders
17:27 EST Ovid Therapeutics (OVID) files to sell 125.06M shares of common stock for holders
Ovid Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $3 price target The firm views Ovid’s OV329 as a “differentiated” oral agent targeting…
Ovid Therapeutics appoints Kaufmann as Chief Medical Officer
Ovid Therapeutics (OVID) announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid from Vigil Neuroscience where she served as Chief Medical ...